Safety and efficacy of different loading doses followed by pro re nata regimens of Conbercept in the treatment of diabetic macular edema

Ting Meng; Hong-yan Sun; Bin Luo; Jing Wang; Li-yu Wang; Ya-li Gao; Li Jiang; Jun Wang; Ting-ming Deng; Ai-neng Zeng; Xiao-ling Luo; Ming-ming Yang

Return

Safety and efficacy of different loading doses followed by pro re nata regimens of Conbercept in the treatment of diabetic macular edema

VernacularTitle:康柏西普不同给药方案治疗DME的安全性和疗效评估
Author: Ting MENG ^{1
,

2
,

3} ; Hong-Yan SUN ^{1
,

2
,

3} ; Bin LUO ^{1
,

2
,

3} ; Jing WANG ^{1
,

2
,

3} ; Li-Yu WANG ^{1
,

2
,

3} ; Ya-Li GAO ^{1
,

2
,

3} ; Li JIANG ^{1
,

2
,

3} ; Jun WANG ^{1
,

2
,

3} ; Ting-Ming DENG ^{1
,

2
,

3} ; Ai-Neng ZENG ^{1
,

2
,

3} ; Xiao-Ling LUO ^{1
,

2
,

3} ; Ming-Ming YANG ^{1
,

2
,

3}
Author Information

1. Shenzhen People's Hospital
2. the Second Clinical Medical College of Jinan University
3. the First Affiliated Hospital of Southern University of Science and Technology, Shenzhen 518003, Guangdong Province, China
Publication Type:Journal Article
Keywords: Conbercept; diabetic macular edema(DME); pro re nata; best corrected visual acuity; central macular thickness; times of injection
From: International Eye Science 2023;23(1):138-141
CountryChina
Language:Chinese
Abstract: AIM: To evaluate the efficacy and safety of different Conbercept treatment on diabetic macular edema(DME)with 3+PRN and 5+PRN.METHODS: Retrospective case-control study. A total of 51 patients(92 eyes)with DME who were treated in our hospital during December 2019 and June 2020 were included, and they were divided into 3+PRN group with 26 cases(48 eyes)and 5+PRN group with 25 cases(44 eyes). All patients received monthly follow-up for 12mo and the changes of best-corrected visual acuity(BCVA)and central macular thickness(CMT), the number of intravitreal injections and the occurrence of complications were compared and observed in the two groups.RESULTS:After follow-up for 12mo, there was no difference in the average injection times between the 3+PRN group and the 5+PRN group(7.24±0.91 times vs. 7.56±1.04 times, P=0.117). The BCVA and CMT of the two groups improved at 3, 6, 9, and 12mo after treatment compared with those before treatment(all P<0.05), and the BCVA and CMT of the 5+PRN group were better than those of the 3+PRN group at 6, 9, and 12mo after treatment(all P<0.05). During the follow-up period, no serious adverse events occurred in the two groups of patients, and the total incidence of ocular adverse events in the two groups was 27%. All adverse events were improved after symptomatic treatment.CONCLUSION: Both the 3+PRN and 5+PRN treatment strategy of Conbercept can treat DME safely and effectively, the total times of injection were comparable. However, the BCVA and CMT improved more in the 5+PRN group than that in 3+PRN group.